Why drug prices will continue to roil the waters-and why Scott Gottlieb, MD, will be in the center of the action.

We'll see what happens to the administration's Part B proposal. Congress is not likely to take bold action, partly because drugmakers are a strong influence on both parties. That leaves the FDA and Administrator Scott Gottlieb, MD, as major players in efforts to rein in drug prices.